期刊
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
卷 129, 期 18, 页码 5798-+出版社
AMER CHEMICAL SOC
DOI: 10.1021/ja069336k
关键词
-
资金
- NCI NIH HHS [R21/33-CA114463] Funding Source: Medline
LDL particles are high-capacity nanocarriers with precisely controlled size and are naturally biocompatible, biodegradable, and nonimmunogenic. However, their utilities as drug carriers are limited by the narrow purview of LDL receptor-positive tumors. Here, we synthsized a ligand-conjugated, NIR-labeled LDL that enables the first in vivo demonstration of rerouting LDL from LDL receptors to selected alternate receptors, thus drastically expanding the range of using LDL particles as nanocarriers for in vivo cancer imaging and treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据